Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038831
Status:
COMPLETED
Last Update Posted:
2012-08-01
First Post:
2002-06-05
Brief Title:
Allo Transplantation With Mylotarg Fludarabine and Melphalan for AML CML and MDS
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Chronic Lymphocytic Leukemia |
| Acute Myelogenous Leukemia |
| Myelodysplastic Syndrome |
Keywords:
| Name | View |
|---|---|
| Acute Myelogenous leukemia | View |
| AML | View |
| Myelodysplastic Syndrome | View |
| MDS | View |
| Chronic Lymphocytic Leukemia | View |
| CML | View |
| Mylotarg | View |
| Gemtuzumab | View |
| Gemtuzumab ozogamicin | View |
| Melphalan | View |
| Alkeran | View |
| Fludarabine Phosphate | View |
| Fludarabine | View |
| Fludara | View |
| Anti-thymocyte globulin | View |
| ATG | View |
| Allogeneic Bone Marrow | View |
| Peripheral Blood Stem Cell Transplantation | View |
| Allo PBSCT | View |
| Allogeneic transplantation | View |